Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.
It operates various active pre-clinical programs.
The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.
Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | 0.31 Increased by +3.33% | 0.33 Decreased by -6.06% |
| May 2, 24 | 0.29 Increased by +480.00% | 0.14 Increased by +107.14% |
| Feb 14, 24 | 0.14 Increased by +16.67% | 3.99 Decreased by -96.49% |
| Nov 7, 23 | 0.47 Decreased by -11.32% | 3.14 Decreased by -85.03% |
| Aug 3, 23 | 0.30 Decreased by -26.83% | 2.18 Decreased by -86.24% |
| May 10, 23 | 0.05 Decreased by -54.55% | 0.65 Decreased by -92.31% |
| Feb 22, 23 | 0.12 Decreased by -29.41% | 3.15 Decreased by -96.19% |
| Nov 9, 22 | 0.53 Increased by +152.38% | 1.65 Decreased by -67.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 5.54 B Increased by +16.78% | 1.27 B Decreased by -40.54% | Increased by +22.85% Decreased by -49.08% |
| Jun 30, 24 | 5.40 B Increased by +28.68% | 1.41 B Increased by +3.76% | Increased by +26.06% Decreased by -19.37% |
| Mar 31, 24 | 4.14 B Increased by +45.16% | 1.32 B Increased by +530.95% | Increased by +31.98% Increased by +334.65% |
| Dec 31, 23 | 4.68 B Decreased by -10.50% | 640.00 M Increased by +9.59% | Increased by +13.68% Increased by +22.45% |
| Sep 30, 23 | 4.74 B Increased by +16.08% | 2.13 B Decreased by -17.54% | Increased by +44.88% Decreased by -28.96% |
| Jun 30, 23 | 4.20 B Increased by +32.76% | 1.36 B Decreased by -28.24% | Increased by +32.32% Decreased by -45.95% |
| Mar 31, 23 | 2.85 B Increased by +34.69% | 210.00 M Decreased by -54.84% | Increased by +7.36% Decreased by -66.47% |
| Dec 31, 22 | 5.23 B Increased by +99.58% | 584.00 M Decreased by -18.44% | Increased by +11.17% Decreased by -59.13% |